Repligen | RGEN - Ebit


Repligen reported $24.31M in EBIT for its fiscal quarter ending in September of 2026.





Ebit Change Date
Agilent USD 444M 45M Jun/2026
Align Technology USD 193.04M 1.72M Sep/2026
Bio Techne USD 75.49M 21.03M Mar/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Bruker USD 69.6M 59.4M Jun/2026
Charles River Laboratories USD 119.89M 9K Jun/2026
Danaher USD 1.25B 118M Sep/2026
Dentsply International USD 84M 52M Jun/2026
General Electric Aerospace USD 2.22B 123M Sep/2026
Henry Schein USD 200M 6M Jun/2026
Illumina USD 260M 21M Jun/2026
IQVIA Holdings USD 608M 1.99B Sep/2026
Mettler Toledo International USD 287.55M 53.61M Jun/2026
Myriad Genetics USD -3M 20.3M Dec/2025
OraSure Technologies USD -13.59M 2.13M Dec/2025
Pacific Biosciences Of California USD -53.19M 35.08M Dec/2025
Pfizer USD -180M 5.16B Jun/2026
Repligen USD 24.31M 3.18M Sep/2026
Revvity USD 126.14M 43.36M Jun/2026
Standard Biotools USD -9.42M 12.51M Mar/2026
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
Waters USD 10M 138M Jun/2026
West Pharmaceutical Services USD -199.7M 378.8M Sep/2026